COVID-19 Vaccine for Inhalation Approved in China
CanSino Biologics Inc. recently announced that the National Medical Products Administration of China had granted the Company approval for its needle-free Recombinant COVID-19 Vaccine for Inhalation, Convidecia Air™.
Convidecia Air provides a non-invasive option that uses a nebulizer to change liquid into an aerosol for inhalation through the mouth, inducing comprehensive immune protection in response to the SARS-CoV-2 coronavirus after just one breath.
Studies published in The Lancet indicated that Convidecia Air could induce strong humoral, cellular and mucosal immunity to achieve triple protection and effectively contain the infection and spread of the virus.
CanSinoBIO received the approval of its clinical trial application for Convidecia Air in March 2021.
Confirmed by the company on September 4, 2022, the inhaled vaccine utilizes the same adenovirus vector technological platform as the intramuscular version Convidecia™.
Currently, CanSinoBIO has achieved steady production of various innovative vaccines and established a global supply chain, with a goal to continue to make quality vaccine products more accessible to the worldwide population.
Note: This announcement was manually translated and curated for mobile readers.